Compare Moderna, Inc. (MRNA) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Snap Inc — how do they compare? Moderna, Inc. trades at $135.88 (market cap $56.02B), while Snap Inc trades at $5.31 (market cap $9.18B). The key difference: Moderna, Inc. is far larger — about 6.1× Snap Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | SNAP | |
|---|---|---|
Market Cap | $56.02B | $9.18B |
Sector | Health | Media |
52-Week High | $174.38 | $9.09 |
52-Week Low | $22.36 | $3.93 |
Enterprise Value | $52.17B | $10.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Snap Inc. (SNAP) trades at $5.43, down 0.73% with a bullish technical signal despite recent legal pressures. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M net income). Analyst consensus is mixed with 38% buy ratings and a $7.02 price target, while recent news highlights leadership changes and ongoing youth-safety lawsuits.
Snap presents a turnaround story with operational improvements but faces significant legal and competitive risks. The stock offers potential upside to analyst targets if execution continues, though persistent losses and regulatory challenges warrant caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
